Scott Fidel

Q: What is Scott Fidel's success rate?

Scott Fidel currently has a success rate of 93.43797335585558.

Q: What is the average return of Scott Fidel's calls?

Their stock ratings have generated an average return of 15.538151489668342.

Goldman Sachs | Healthcare

Scott Fidel is an analyst from Goldman Sachs specializing in the Healthcare sector. Ranked #1335 out of 4673 analysts, they have issued 23 stock ratings with a success rate of 93.44% and an average return of 15.54%.

Scott Fidel has a well-established track record, with 23 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 93.44% and an average return of 15.54%, underscoring their expertise and ability to identify winning opportunities for investors.

#1335

Out of 4673

Total Ratings

+93.44%

Success Rate

+15.54%

Average Return

Recent Ratings Analysis

BTSG

Buy

Jun 08, 2026

Target

$71.00

Current

$59.22

Performance

0.00%

Scott Fidel rated BTSG as Buy on Jun 08, 2026, setting a price target of 71. Shares have remained stable near 59.22, leaving the 71 target still in play.

OPCH

Hold

Jun 08, 2026

Target

$22.00

Current

$20.08

Performance

0.00%

On Jun 08, 2026, OPCH was given a Neutral rating by Scott Fidel, with a target price of 22. Market indecision, reflected in sideways trading near 20.08, supported the cautious call.

GMRS

Buy

Jun 08, 2026

Target

$35.00

Current

$10.58

Performance

0.00%

GMRS received a Buy rating from Scott Fidel on Jun 08, 2026, aiming for 35. Price action was muted, as shares hovered around 10.58 despite the bullish outlook.

LFST

Hold

Jun 05, 2026

Target

$9.00

Current

$7.34

Performance

-0.94%

On Jun 05, 2026, Scott Fidel published a Neutral outlook on LFST, with a target of 9. Sideways action left the Hold view intact, with no major move since 7.34.

CON

Buy

Jun 05, 2026

Target

$30.00

Current

$25.46

Performance

0.55%

Scott Fidel on Jun 05, 2026 assigned CON a Buy rating, with a price target of 30. The recommendation remains pending validation as shares consolidate around 25.46.

AVAH

Buy

May 15, 2026

Target

$11.00

Current

$6.64

Performance

-13.99%

On May 15, 2026, Scott Fidel reaffirmed AVAH with a Overweight rating, targeting 11. Shares slid 13.99% despite the recommendation, highlighting downside risks.

ADUS

Buy

Feb 25, 2026

Target

$140.00

Current

$90.71

Performance

-15.70%

ADUS was rated Overweight by Scott Fidel on Feb 25, 2026, with a price objective of 140. This case shows how bullish projections can fail, with the stock now below 90.71.

MOH

Hold

Feb 12, 2026

Target

$167.00

Current

$198.41

Performance

56.59%

On Feb 12, 2026, Scott Fidel initiated coverage on MOH with a Neutral rating and target of 167. The Hold stance underestimated the stock’s strength as it gained 56.59%.

GRDN

Buy

Jan 14, 2026

Target

$36.00

Current

$40.51

Performance

34.45%

Scott Fidel issued a Overweight recommendation for GRDN on Jan 14, 2026, price target set at 36. Investors following the Buy call captured upside momentum, with shares now at 40.51.

ARDT

Buy

Nov 14, 2025

Target

$17.00

Current

$8.83

Performance

-2.00%

On Nov 14, 2025, ARDT was evaluated by Scott Fidel, who gave a Overweight rating and target of 17. So far, the Buy call awaits clearer momentum, with shares flat at 8.83.

CI

Buy

Nov 04, 2025

Target

$330.00

Current

$289.61

Performance

9.43%

Scott Fidel rated CI as Buy on Nov 04, 2025, setting a price target of 330. The call has proven timely, with shares rising 9.43% toward the price target of 330.

CNC

Sell

Oct 31, 2025

Target

$38.00

Current

$65.03

Performance

83.86%

On Oct 31, 2025, CNC was given a Sell rating by Scott Fidel, with a target price of 38. The Sell stance aligned with downward action, with the stock sliding from 65.03 to 65.03.

HCA

Buy

Oct 27, 2025

Target

$520.00

Current

$361.32

Performance

-22.77%

HCA received a Buy rating from Scott Fidel on Oct 27, 2025, aiming for 520. The rating hasn’t played out as hoped, with the stock trading 22.77% below expectations.

UNH

Buy

Oct 14, 2025

Target

$406.00

Current

$406.57

Performance

12.96%

On Oct 14, 2025, Scott Fidel published a Buy outlook on UNH, with a target of 406. Shares gained 12.96%, underscoring the accuracy of the bullish outlook toward 406.

UHS

Hold

Oct 14, 2025

Target

$219.00

Current

$142.87

Performance

-29.90%

Scott Fidel on Oct 14, 2025 assigned UHS a Neutral rating, with a price target of 219. The call successfully avoided chasing as shares lost 29.90%.

THC

Buy

Oct 14, 2025

Target

$224.00

Current

$163.01

Performance

-16.97%

On Oct 14, 2025, Scott Fidel reaffirmed THC with a Buy rating, targeting 224. Shares slid 16.97% despite the recommendation, highlighting downside risks.

OSCR

Hold

Oct 14, 2025

Target

$17.00

Current

$27.39

Performance

32.38%

OSCR was rated Neutral by Scott Fidel on Oct 14, 2025, with a price objective of 17. Despite caution, upside momentum rewarded risk-takers with gains to 27.39.

ELV

Hold

Oct 14, 2025

Target

$343.00

Current

$418.15

Performance

19.31%

On Oct 14, 2025, Scott Fidel initiated coverage on ELV with a Neutral rating and target of 343. The Hold stance underestimated the stock’s strength as it gained 19.31%.

ALHC

Buy

Oct 14, 2025

Target

$21.00

Current

$15.35

Performance

-11.07%

Scott Fidel issued a Buy recommendation for ALHC on Oct 14, 2025, price target set at 21. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

CVS

Buy

Oct 14, 2025

Target

$91.00

Current

$97.08

Performance

21.87%

On Oct 14, 2025, CVS was evaluated by Scott Fidel, who gave a Buy rating and target of 91. This case illustrates how a timely bullish rating can translate into tangible gains of 21.87%.

PNTG

Buy

Mar 11, 2025

Target

$38.00

Current

$31.38

Performance

35.32%

Scott Fidel rated PNTG as Overweight on Mar 11, 2025, setting a price target of 38. The call has proven timely, with shares rising 35.32% toward the price target of 38.

AMED

Hold

Mar 04, 2025

Target

$101.00

Current

$100.99

Performance

9.65%

On Mar 04, 2025, AMED was given a Equal-Weight rating by Scott Fidel, with a target price of 101. The stock rallied from 100.99 to 100.99 after the Hold rating, surprising to the upside.

PACS

Buy

Nov 18, 2024

Target

$31.00

Current

$35.07

Performance

107.15%

PACS received a Overweight rating from Scott Fidel on Nov 18, 2024, aiming for 31. Momentum has favored the Buy call, with shares climbing from 35.07 to 35.07, rewarding those who trusted the recommendation.

HUM

Hold

Oct 09, 2024

Target

$250.00

Current

$355.98

Performance

45.03%

On Oct 09, 2024, Scott Fidel published a Equal-Weight outlook on HUM, with a target of 250. The Hold call missed some of the bullish momentum as shares advanced toward 250.

Frequency Asked Questions

Who is Scott Fidel?

Scott Fidel is an analyst from Goldman Sachs specializing in the Healthcare sector.

What is Scott Fidel's success rate?

Scott Fidel currently has a success rate of +93.44%.

How many ratings has Scott Fidel issued?

Scott Fidel has issued 23 stock ratings so far.

What is the average return of Scott Fidel's calls?

Their stock ratings have generated an average return of +15.54%.

What is Scott Fidel's ranking?

Scott Fidel is ranked #1335 out of 4673 analysts.

What types of ratings does Scott Fidel give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Scott Fidel?

You can follow Scott Fidel by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Scott Fidel?

Their latest rating was a Buy on BTSG issued on 2026-06-08.